TITLE:
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

CONDITION:
Anemia

INTERVENTION:
Darbepoetin Alfa

SUMMARY:

      The purpose of this trial is to demonstrate benefit with respect to hematopoietic response
      in subjects with anemia of cancer randomized to Darbepoetin Alfa once every 4 weeks.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Eligibility Criteria: - Subjects with non-myeloid malignancies - Subjects can not be on
        chemotherapy - Anemia of cancer - Eastern Cooperative Oncology Group (ECOG) status of 0 to
        2 - Hemoglobin less than or equal to 11.0 g/dL - Adequate renal and liver function -
        Written informed consent
      
